Shares of Telomir Pharmaceuticals climbed up 20% to $5.10 after the company said it saw positive pre-clinical results confirming the efficacy of its licensed molecule Telomir-1 in reversing several ...
(HealthDay News) — Younger age at diagnosis of type 2 diabetes is significantly associated with a higher risk for subsequent dementia, according to a study published online in PLOS ONE.
MIAMI, FL / / December 3, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ('Telomir' or the 'Company'), an emerging leader in age-reversal science, today announced groundbreaking preclinical ...